0.3% hypromellose
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Corneal Epithelium Defect
Conditions
Corneal Epithelium Defect
Trial Timeline
Oct 1, 2007 → Oct 1, 2009
NCT ID
NCT00598689About 0.3% hypromellose
0.3% hypromellose is a approved stage product being developed by Novartis for Corneal Epithelium Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00598689. Target conditions include Corneal Epithelium Defect.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00598689 | Approved | Completed |
Competing Products
12 competing products in Corneal Epithelium Defect